Leerink Partners maintained a positive outlook on shares of Eli Lilly and Company (NYSE:LLY) shares, reiterating an Outperform rating and a price target of $950.00. The pharmaceutical giant, currently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback